Trial Profile
A Pilot Study of Immune Checkpoint Inhibition (Durvalumab With or Without Tremelimumab) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 26 Mar 2021 Status changed from active, no longer recruiting to completed.
- 29 Jan 2020 Results of phase I part of this study published in the Clinical Cancer Research.
- 23 Aug 2019 Status changed from recruiting to active, no longer recruiting.